Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Shuyu Zhai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7319-1571; OpenAlex author ID A5021065095. Sources: OpenAlex.

Their work

Papers
15 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2019: 4 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers · 2025: 3 papers

Papers 15

  1. H19 promotes polarization and alternative splicing in tumor-associated macrophages, facilitating pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2024.217389↗
  2. CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization. Co-author DOI 10.1038/s41418-024-01423-1↗
  3. Identification of a Novel Small Molecule STING Agonist Reshaping the Immunomicroenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/ijbs.107837↗
  4. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Co-author DOI 10.1002/advs.202306298↗
  5. ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma. Co-author DOI 10.1007/s13402-023-00907-5↗
  6. A microprotein N1DARP encoded by LINC00261 promotes Notch1 intracellular domain (N1ICD) degradation via disrupting USP10-N1ICD interaction to inhibit chemoresi… Co-author DOI 10.1038/s41421-023-00592-6↗
  7. Hypoxia-induced long non-coding RNA LINC00460 promotes p53 mediated proliferation and metastasis of pancreatic cancer by regulating the miR-4689/UBE2V1 axis an… Co-author DOI 10.7150/ijms.87833↗
  8. Comprehensive machine learning-generated classifier identifies pro-metastatic characteristics and predicts individual treatment in pancreatic cancer: A multice… Co-author DOI 10.7150/thno.84978↗
  9. Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1. Co-author DOI 10.1186/s13045-022-01348-7↗
  10. Positive feedback between lncRNA FLVCR1-AS1 and KLF10 may inhibit pancreatic cancer progression via the PTEN/AKT pathway. First author DOI 10.1186/s13046-021-02097-0↗
  11. Construction and integrated analysis of a lncRNA-associated competing endogenous RNA network reveal functional lncRNAs in pancreatic cancer. Co-author DOI 10.21037/tcr.2020.04.03↗
  12. Comparison of Radical Antegrade Modular Pancreatosplenectomy with Standard Retrograde Pancreatosplenectomy for Left-Sided Pancreatic Cancer: A Meta-Analysis an… First author DOI 10.12659/msm.914540↗
  13. TRIANGLE operation for borderline resectable pancreatic cancer in total pancreatectomy. Co-author DOI 10.21037/tcr.2019.09.50↗
  14. PRPF40A as a potential diagnostic and prognostic marker is upregulated in pancreatic cancer tissues and cell lines: an integrated bioinformatics data analysis. First author DOI 10.2147/ott.s206039↗
  15. INPP4B As A Prognostic And Diagnostic Marker Regulates Cell Growth Of Pancreatic Cancer Via Activating AKT. Co-author DOI 10.2147/ott.s223221↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 10 shared papers, 2019–2025 · strength 1.44
  2. Yizhi Cao · 7 shared papers, 2023–2025 · strength 1.25
  3. Xiaxing Deng · 7 shared papers, 2019–2024 · strength 0.96
  4. Xiaomei Tang · 7 shared papers, 2019–2024 · strength 0.94
  5. Pengyi Liu · 5 shared papers, 2023–2025 · strength 0.89
  6. Jiayu Lin · 4 shared papers, 2024–2025 · strength 0.80
  7. Chenghong Peng · 5 shared papers, 2021–2025 · strength 0.80
  8. Yang Liu · 4 shared papers, 2024–2025 · strength 0.77
  9. Weishen Wang · 5 shared papers, 2020–2024 · strength 0.77
  10. Chenlei Wen · 4 shared papers, 2023–2025 · strength 0.69
  11. Lingxi Jiang · 4 shared papers, 2021–2025 · strength 0.64
  12. Xiaxing Deng · 5 shared papers, 2019–2024 · strength 0.62
  13. Jiewei Lin · 4 shared papers, 2021–2025 · strength 0.61
  14. Yihao Liu · 3 shared papers, 2024–2025 · strength 0.52
  15. Ronghao Zhang · 3 shared papers, 2023–2024 · strength 0.47
  16. Yuanchi Weng · 4 shared papers, 2019–2020 · strength 0.40
  17. Zhen Huo · 4 shared papers, 2019–2020 · strength 0.40
  18. Hao Qian · 4 shared papers, 2019 · strength 0.38
  19. Yishu Huang · 2 shared papers, 2023–2025 · strength 0.38
  20. Baiyong Shen · 2 shared papers, 2022–2025 · strength 0.37
  21. Dongjie Chen · 2 shared papers, 2023–2025 · strength 0.36
  22. Youwei Zhu · 2 shared papers, 2024 · strength 0.34
  23. Shulin Zhao · 3 shared papers, 2019–2023 · strength 0.33
  24. Xinjing Wang · 2 shared papers, 2022–2023 · strength 0.32
  25. Siyi Zou · 2 shared papers, 2021–2025 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.